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The human immunodeﬁciency virus type I (HIV-1) Vpr plays an essential role in viral replication. A
number of studies have reported that Vpr modulates the nuclear factor-kB (NF-kB) pathway. Yet, the
reported effects of Vpr on NF-kB signaling are controversial. In this study, we investigate the interplay
between Vpr and NF-kB pathway. We discover that HIV-1 infection elevates the phosphorylation of
IkBa and p100, and that this increase is greatly reduced when a Vpr-negative HIV-1 is used for
infection. Our data further show that Vpr regulates the activity of IKKa/b through interactions. In
addition, Vpr modulates the phosphorylation of p65 and p100, suggesting that Vpr activates both
canonical and noncanonical NF-kB pathway. Knock down of endogenous IKKa/b result in a decrease in
Vpr-mediated NF-kB and HIV-1 LTR activation. Given that Vpr is present in HIV-1 particles, our data
suggest that Vpr activates the NF-kB pathway immediately after HIV-1 entry.
& 2013 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus type I (HIV-1) encodes a
14 kDa accessory protein named viral protein R (Vpr). Vpr is
expressed at the late stage of HIV-1 infection and located both in
the cytoplasm and the nucleus of HIV-infected cells (Cohen et al.,
1990; Jacquot et al., 2007; Subbramanian et al., 1998). In addition
to HIV-1, all other primate lentiviruses encode Vpr (Tristem et al.,
1992, 1998). Vpr is incorporated into HIV-1 particles through a
direct interaction with the p6 domain of Gag (Muller et al., 2000),
which suggests a role of Vpr at the early stage of HIV-1 infection.
Interestingly, Vpr protein is present in sera and cerebrospinal
ﬂuid (CSF) of AIDS patients (Levy et al., 1994, 1995; Paxton et al.,
1993; Tungaturthi et al., 2003), implicating its diverse impacts on
the host.
Vpr plays an important role in HIV-1 replication and patho-
genesis. Deletion of Vpr reduces viral replication (Tungaturthi
et al., 2003). Multiple functions have been discovered for Vpr,
these include promoting the nuclear transport of the viral pre-
integration complex (PIC), enhancing the ﬁdelity of the reversell rights reserved.
iao).
.transcription, inducing cell cycle G2/M arrest, regulating apopto-
sis, and transactivating HIV-1 LTR as well as host cell genes. In
addition, Vpr has also been shown to interact with a number of
cellular proteins including transcription factors Sp1, TFIIB, p300/
CBP, glucocorticoid receptor type II complex, Lys-tRNA synthe-
tase, uracil DNA glycosylase, cyclophilin A, heat shock protein 70
(Gummuluru and Emerman, 1999; Wang et al., 1995). Among
these interactions, association with Sp1 and TFIIB transcription
factors enables Vpr to enhance the transcription activity of of
HIV-1 LTR promoter (Gummuluru and Emerman, 1999; Wang
et al., 1995). Vpr also regulates the production of IL-6, IL-8 in a
nuclear factor-kB (NF-kB)-dependent manner (Hoshino et al.,
2010; Roux et al., 2000).
NF-kB belongs to a class of dimeric transcription factors of the
Rel family, which actively participate in the regulation of immu-
nity, inﬂammation, cell proliferation and survival (Karin and Ben-
Neriah, 2000; Kucharczak et al., 2003). The NF-kB family consists
of ﬁve members: p105/p50 (NF-kB1), p100/p52 (NF-kB2), p65
(RelA), c-Rel and RelB. These proteins exist in the form of
homodimers or heterodimers to transactivate numerous target
genes via binding to the kB enhancer (Hayden and Ghosh, 2004).
The NF-kB pathways are classiﬁed into canonical and noncano-
nical ones (Hacker and Karin, 2006). In unstimulated cells, NF-kB
dimers are sequestered in the cytoplasm as a result of the
association with the IkB protein (IkBa or p100). Exposure of cells
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R. Liu et al. / Virology 439 (2013) 47–5648to a variety of stimuli leads to IkB (IkBa or p100) phosphorylation
by IkB kinase (IKK), polyubiquitination and proteasomal degrada-
tion. As a result, NF-kB dimers dissociate from IkB (IkBa or p100),
translocate to the nucleus and regulate transcription of target
genes (Skaug et al., 2009). Several stimuli such as tumor necrosis
factor a (TNFa), interleukin-1b (IL-1b), bacterial lipopolysacchar-
ides (LPS) and viral nucleic acids can activate the canonical
pathway which leads to the phosphorylation of IkBa by IKKb.
Whereas a subset of receptors in B cells, such as CD40 and B-cell
activating factor receptor (BAFF-R), can activate the noncanonical
pathway. The latter pathway involves the induction of kinase
(NIK) and IKKa to regulate the phosphorylation on 866 and 870,
ubiquitination and the processing of p100 into the mature
subunit p52 (Amir et al., 2004; Sun, 2011).
Activation of NF-kB is a hallmark of virus infection. In the case
of HIV-1, several viral components have been shown to stimulate
the NF-kB pathway (Santoro et al., 2003). These include HIV-1
RNA, viral gp120, gp41, Tat and Nef (Bren et al., 2009; Demarchi
et al., 1999; Fortin et al., 2004; Ishii et al., 2001; Mingyan et al.,
2009; Postler and Desrosiers, 2012). The outcome of activating
the NF-kB pathway is the transactivation of the HIV-1 LTR and
increase in viral gene expression. In addition to these HIV-1
components, Vpr has also been reported to affect the activity of
NF-kB pathway albeit with seemingly controversial impacts. For
example, it has been reported that the synthetic Vpr activates NF-
kB pathway and stimulates HIV-1 transcription in U937 and
primary macrophages (Varin et al., 2005). In contrast, Vpr that
is expressed from an adenoviral vector prevents TNFa from
activating the NF-kB pathway (Kogan et al., 2012). In this study,
we provide evidence showing that Vpr, in the context of HIV-1
infection, promotes the phosphorylation of IkBa and p100, and
thereby activates both canonical and noncanonical NF-kB path-
way and HIV-1 LTR. Our data further show an association of Vpr
with IKKa/b, which suggests a direct effect of Vpr on the NF-kB
pathway.α-Pi-IκBα
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Fig. 1. Vpr induces phosphorylation of IkBa. (A) Schematic representation of
NLENY1-ES-IRES and NLENY1-DVpr viruses. A mutated start codon of vpr gene
was introduced in NLENY1-ES to generate NLENY1-DVpr. (B) HEK293T cells were
transfected with 0.5 mg VSV-G along with 5 mg NLENY1-ES or NLENY1-DVpr by
Lipofectamine 2000. The cells and viral supernatants were subjected to Western
blotting and probed with indicated antibodies. (C) A total of 0.5106 HEK293T
cells were transfected with 0.3 mg Flag-IkBa. Twenty-four hours post-transfection,
cells were infected with VSV-G pseudotyped NLENY1-ES or NLENY1-DVpr (ES and
DVpr for short) equivalent to 200 ng p24 for 2 h. Cell lysates were subjected to
Western blotting and probed with indicated antibodies. (D and E) Vpr induces
phosphorylation of IkBa on Ser32 and Ser36. A total of 0.5106 HEK293T cells
were transfected with 0.5 mg pIkBa (D) or pIkBa (AA) (E) and increasing amounts
of Flag-Vpr. Total DNA amounts were adjusted to 2 mg with an empty vector.
Forty-eight hours post-transfection, cells were stimulated with 20 ng/ml of TNFa
for 5 min as a positive control. Whole cell lysates were harvested and probed with
indicated antibodies.Results
Vpr induces phosphorylation of IkBa
We ﬁrst asked whether virion-associated Vpr is able to
enhance the phosphorylation of IkBa that signals the activation
of NF-kB pathway. To answer this question, we mutated the
translation start codon of Vpr in the context of the NLENY1-ES-
IRES proviral DNA clone and generated NLENY1-DVpr (Fig. 1A).
We then produced VSV-G pseudotyped HIV-1 virus particles by
transfecting HEK293T cells with HIV-1 DNA NLENY1-ES-IRES and
NLENY1-DVpr together with the pVSV-G DNA. Results of Western
blotting showed that the NLENY1-DVpr DNA did not express Vpr
as a result of the inserted mutation in Vpr (Fig. 1B). Both NLENY1-
ES-IRES and NLENY1-DVpr expressed similar levels of Gag protein
and produced similar amounts of virus particles (Fig. 1B). The
NLENY1-ES-IRES viruses but not NLENY1-DVpr carried Vpr
(Fig. 1B). Next, we used the same amounts of NLENY1-ES-IRES
and NLENY1-DVpr to infect HEK293T cells that ectopically
expressed Flag-IkBa. To rule out the possible effect of newly
synthesized viral proteins (e.g., Tat and Nef) on the activation of
NF-kB pathway, we harvested the infected cells 2 h after infec-
tion. Levels of total IkBa and its phosphorylated form were
determined by Western blotting. Results of Fig. 1C show that
phosphorylation of IkBa was notably increased following infec-
tion by the NLENY1-ES-IRES virus but not by NLENY1-DVpr. In
order to further demonstrate that it is Vpr, not other HIV-1
proteins, which caused IkBa phosphorylation, we transfected HeLa
cells with plasmids expressing IkBa and Flag-Vpr. Human TNFawas used as a positive control since it can potently induce the
phosphorylation of IkBa. Results of Fig. 1D show that Flag-Vpr
itself induced the phosphorylation of IkBa to a level similar to that
by TNFa. Mutating the Ser32 and Ser36 residues rendered the IkBa
(AA) mutant not being phosphorylated in response to the stimula-
tion by Vpr or TNFa (Fig. 1E). Together, these results demonstrate
that Vpr promotes the phosphorylation of IkBa during HIV-1
infection, which is consistent with the reported activation of NF-
kB pathway by the synthetic or puriﬁed Vpr (Hoshino et al., 2010;
Varin et al., 2005).
R. Liu et al. / Virology 439 (2013) 47–56 49Vpr associates with the IKK complex and modulates
its phosphorylation
Given that IkBa is phosphorylated by the IKK complex, we
speculate that Vpr may enhance IkBa phosphorylation through
modulating the activity of IKK. To explore this possibility, we ﬁrst
test whether Vpr associates with IKK. The IKK complex consists of
two catalytic subunits (IKKa and IKKb) and an essential regula-
tory subunit IKKg (also known as NEMO or IKKAP). We therefore
expressed Vpr with each of these three subunits and performed
co-immunoprecipitation experiments. The results showed that
Vpr associated with IKKa and IKKb, but not with IKKg (Fig. 2A and
B). Further supporting this observed interaction, Vpr also co-
immunoprecipitated with the endogenous IKKa and IKKb (Fig. 2C
and D).
We next examined whether the association with IKK enables
Vpr to modulate IKK phosphorylation. First, we transfected
HEK293T cells with HA-IKKa or IKKa (AA) (Serine 176 and 180
were both replaced by alanine) along with Flag-Vpr or Myc-NIK.
As shown in Fig. 2E, Vpr signiﬁcantly increased phosphorylation
of IKKa, whereas the IKKa (AA) mutant was completely un-
phosphorylated. Similarly, Vpr also promoted the phosphoryla-
tion of IKKb and mutating the Ser177 and Ser181 residues ablated
IKKb phosphorylation (Fig. 2F). To further assess the effect of Vpr
on the phosphorylation of IKK in HIV-1 permissive cells, we
transduced Jurkat cells with VSV-G pseudotyped lentiviral VLPs
carrying Flag-Vpr. After 48 h, cells were treated with 12.5 nM
Calyculin A (a serine/threonine phosphatase inhibitor of both PP1
and PP2A families) for 5 min prior to harvest. Results of Fig. 2G
demonstrate that Vpr notably enhances the phosphorylation of
IKKa/b in Jurkat cells in the presence of Calyculin A (Fig. 2G lanel
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Fig. 2. Vpr associates with the IKK complex and modulates its phosphorylation. (A)
transfected with the indicated plasmids, and the cell lysates were coimmunoprecipitate
antibodies. (B) Vpr interacts with IKKb, but not IKKg. HEK293T cells were transfec
coimmunoprecipitated with anti-Myc antibody. Samples from both cell lysates and im
Endogenous IKKa (C) and IKKb (D) are associated with Vpr. A total of 1107 HEK293T
carried out with the indicated antibodies. (E) Vpr enhances phosphorylation of IKKa on
IKKa (AA), along with Flag-Vpr or Myc-NIK. Forty-eight hours after transfection, cell lysa
the phosphorylation of IKKb on Ser 177/181. HEK293T cells were transfected with the i
treated with TNFa (20 ng/ml). Cell lysates were assessed by Western blotting with ind
Jurkat cells (2106) were transduced with VSV-G pseudotyped lentiviral VLPs carrying
for 5 min. Whole cell lysates were subjected to Western blotting and probed with ind4). Taken together, these data suggest that Vpr interacts with the
IKK complex and further modulates IKK phosphorylation.
We also tried to determine the key amino acids of Vpr that are
involved in modulating the IKK activity. We chose to study three
Vpr mutants namely A30L, R77Q and S79A. The A30L mutation was
reported to impair the incorporation of Vpr into virions and the
ability of Vpr to cause G2/M cell cycle arrest. R77Q was a high
frequency mutant in long-term non-progressor individuals (LTNPs)
(Lum et al., 2003). Ser79 has been shown to be phosphorylated by
PKA and is crucial for the virion incorporation of Vpr, nuclear
import of Vpr and infectivity of the virus (Agostini et al., 2002;
Barnitz et al., 2010; Zhou and Ratner, 2000). To examine their
ability to induce the phosphorylation of IKKa/b, we transfected
these mutants along with HA-IKKa or IKKb into HEK293T cells
(Fig. 3A and B). Results of co-immunoprecipitation experiments
showed that all three Vpr mutants associated with IKKa and IKKb
(Fig. 3C and D). Then IKKa/b phosphorylation were examined, the
A30L and R77Q mutants failed to stimulate IKKa phosphorylation,
but still increased IKKb phosphorylation. In contrast, Vpr S79A
enhanced the phosphorylation of IKKa, yet exerted no effect on the
phosphorylation of IKKb. Therefore, the A30 and R77 residues play
an important role in Vpr-stimulated phosphorylation of IKKa, and
S79 is required for Vpr-stimulated IKKb phosphorylation.
Vpr activates both canonical and non-canonical
NF-kB signaling pathway
Given that the phosphorylation and degradation of IkBa can
result in the relocation of p65 into the nucleus and subsequent
activation of canonical NF-kB pathway, we proposed that HIV-1
Vpr can also regulate the function of p65. To test this, we assessedC
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HA-IKKb (B) along with 0.5 mg Flag-Vpr or its mutants (A30L, R77Q, S79A). Whole
cell lysates were subjected to Western blotting and probed with indicated
antibodies. Vpr mutants associate with IKKa (C) and IKKb (D) in vivo. HEK293T
cells were transfected with the indicated plasmids. At 48 h after transfection, cells
lysates were immunoprecipitated (IP) with anti-Flag antibody. Samples from both
cell lysates and immunoprecipitates were probed with anti-HA and anti-Flag
antibodies.
R. Liu et al. / Virology 439 (2013) 47–5650the effect of Vpr on the subcellular localization of p65. As shown
in Fig. 4A, p65 was seen in the cytoplasm in the absence of
Flag-Vpr (the top panel), as opposed to its dominant nuclear
localization in cells expressing Flag-Vpr (the bottom panel).
Quantiﬁcation of p65 distribution revealed its 13.3% nucleus
presence in control cells in contrast to 91.5% nucleus localization
in Vpr-positive cells (Fig. 4B). Then we transfected HEK293T cells
with plasmids expressing HA-p65 and Vpr, and examined p65
phosphorylation by Western blotting. Indeed, expression of Vpr
increased the phosphorylation of p65 (Fig. 4C). We further
investigate the effect of Vpr on p65 in Jurkat T cells. Results of
Fig. 4D show that transduction Vpr in a retrovirus vector also
enhanced the phosphorylation of endogenous p65. Together, the
data demonstrate that Vpr promotes the phosphorylation of p65
and relocates p65 from the cytoplasm into the nucleus.
It is known that noncanonical NF-kB pathway also regulates
important physiological functions. So we next investigated
whether Vpr is able to regulate the noncanonical NF-kB signaling,
which is characterized by phosphorylation of p100, processing
p100 into p52 and subsequent nuclear translocation of RelB/p52
complexes. We therefore also tested whether Vpr exerts an effect
on this p100-mediated noncanonical NF-kB pathway. First, we
examined whether Vpr induces phosphorylation of p100. Results
of Fig. 5A show that, following infection of the Jurkat T cells with
VSV-G pseudotyped NLENY1-ES-IRES virus, phosphorylation of
endogenous p100 was signiﬁcantly increased. In contrast, the
NLENY1-DVpr mutated virus failed to exert such an effect. In
order to further demonstrate that Vpr itself induces p100 phos-
phorylation, we transduced Vpr into Jurkat T cells, and examined
p100 phosphorylation by Western blotting. Again, notable
increase of p100 phosphorylation was observed in the presence
of Vpr expression (Fig. 5B lane 2). Similar results were obtained in
HEK293T cells (Fig. 5C lane 2). Concurrent with its phosphoryla-
tion, p100 is cleaved to produce p52, as shown by the results ofWestern blotting (Fig. 5D), and also translocates from the cyto-
plasm into the nucleus (Fig. 5E). The results showed that 9.46% of
p100 was located in the nucleus in control cells, as compared to
75.46% nuclear localization in Vpr-positive cells (Fig. 5F).
We next tried to determine which serine residue(s) in p100 is/
are phosphorylated as a result of Vpr stimulation. To this end, we
generated a panel of p100 mutants by mutating the following
serines S866A, S870A, S872A, 2SA and 3SA (Fig. 5E and F). Results
of Western blotting showed that 2SA and 3SA were not phos-
phorylated in cells expressing Vpr or IKKa (Fig. 5E). In addition,
the S866A mutant exhibited weak phosphorylation signals
(Fig. 5F). Together, the data indicate that Vpr stimulates non-
canonical pathway by enhancing the phosphorylation of p100
at S866.
Vpr activation of HIV-1 LTR depends on NF-kB pathway
We next tested whether this Vpr-induced p65 and p100
phosphorylation and their nuclear relocalization lead to activa-
tion of NF-kB reporter. We found that overexpressed Vpr
increased NF-kB luciferase expression in a dose-dependent man-
ner in both HEK293T and HeLa cells (data not shown).
Given that Vpr causes IkBa phosphorylation via the associa-
tion with IKKa/b, we envisioned that depleting endogenous IKKa/
b should abrogate Vpr-induced activation of NF-kB reporter and
HIV-1 LTR. To test this, we generated IKKa/b knockdown HeLa cell
line. As shown in Fig. 6A, the endogenous IKKa and IKKb were
effectively knocked down. Results of reporter assays showed that
knockdown of IKKa completely disabled Vpr from activating NF-
kB-dependent gene expression, whereas Vpr retained partial
ability with knockdown of IKKb (Fig. 6B). Then we examined
whether knockdown of IKKa/b would affect Vpr-induced trans-
activation of HIV-1 LTR. As shown in Fig. 6C, similar results were
obtained. This ﬁnding indicates that both IKKa and IKKb con-
tribute to Vpr-mediated NF-kB-dependent HIV-1 LTR activation
with IKKa playing a major role.
To further elucidate the contribution of canonical and non-
canonical NF-kB pathways in HIV-1 LTR transactivation, we
generated p65 and RelB knockdown HeLa cell line. It is expected
that depleting endogenous p65 and RelB abrogates the activation
of canonical or noncanonical NF-kB pathway. The efﬁcient knock-
down of p65 and RelB was shown by the results of Western
blotting (Fig. 6D). Results of reporter assays showed that knock-
down of p65 and RelB severely abrogated Vpr to activate NF-kB
and HIV-1 LTR reporters (Fig. 6E and F). This ﬁnding indicates that
both canonical and noncanonical NF-kB pathways contribute to
Vpr-mediated HIV-1 LTR activation.Discussion
Vpr is an important pathogenic determinant of HIV-1, since
deletion of the vpr gene reduces HIV-1 virulence. In addition to
the multiple functions reported for Vpr, the role of Vpr in NF-kB
pathway has also been documented. Yet, results from different
groups about this latter property of Vpr are controversial. Viron-
derived Vpr and extracellular Vpr activate NF-kB pathway, as a
result stimulate HIV-1 LTR transcription and the production of
various cytokines including IL-6 and IL-8 (Hoshino et al., 2010;
Roux et al., 2000; Varin et al., 2005). On the contrary, Vpr that is
expressed from an adenoviral vector inhibits TNFa-stimulated
NF-kB activation (Kogan et al., 2012). In addition, it is not known
how Vpr regulates NF-kB pathway. Here we present data showing
that Vpr, in the absence of external stimuli, activates both canonical
and noncanonical pathway through association with IKKa/b and
enhancing their phosphorylation. In addition, virion-associated Vpr
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R. Liu et al. / Virology 439 (2013) 47–56 51promotes the phosphorylation of IkBa and p100 at the early stage
of HIV-1 infection.
Many viruses activate the NF-kB pathways by targeting the
IKK complex. Not surprisingly, Vpr also regulates the phosphor-
ylation of IKKa/b via interaction with IKKa/b (Fig. 2). As a result,
IKKa and IKKb are indispensable for Vpr-induced NF-kB activa-
tion (Fig. 6). In a fashion similar to HTLV-1 transactivator Tax
(Liang et al., 2006), Vpr also interacts with IKK subunits (IKKa and
IKKb) and regulates IKK kinase activity, activation of downstream
signal cascade.
It is known that HIV-1 exploits several means to activate canonical
NF-kB pathway in order to promote viral replication. For example,
HIV-1 envelope glycoprotein gp120 activates the NF-kB pathway
through binding to the CD4 receptor. HIV-1 regulatory protein Tat
activates NF-kB pathway in two manners. One involves activating
PKC and PKR to stimulate IKKs, the other one is to interact with IkBa
and p65. Our data show that HIV-1 virion-associated Vpr induces
phosphorylation of IkBa (Fig. 1C), which is consistent with the results
of studies using synthetic Vpr (Varin et al., 2005). We also ﬁnd that
Vpr promotes the phosphorylation and nuclear translocation of p65
(Fig. 4). Our ﬁnding further suggests that Vpr is able to activate the
NF-kB pathway at the early stage of viral life cycle prior to the
synthesis of gp120 and Tat. Conceivably, this role of Vpr is to increase
the basal level of HIV-1 gene expression prior to Tat is produced.Besides activation of canonical NF-kB pathway, we discover that
Vpr can also activate noncanonical NF-kB signaling (Fig. 5). Activa-
tion of the noncanonical pathway is relatively slow but persistent as
compared with canonical pathway (Dejardin et al., 2002; Razani
et al., 2011). Increasing evidence shows that noncanonical NF-kB
pathway regulates many biological functions, these include lym-
phoid organogenesis, B-cell survival and maturation, dendritic cell
activation and bone metabolism (Dejardin, 2006). Noncanonical NF-
kB pathway is also known being targeted by some viruses including
HTLV, EBV, BFV and HIV-1 (Manches et al., 2012; Santoro et al., 2003;
Sun, 2011; Wang et al., 2010a). Here, we ﬁrst show that Vpr also
targets the noncanonical NF-kB pathway. It is known that Vpr is
essential for optimal viral replication of HIV-1 in non-dividing cells
such as monocyte-derived macrophages (MDMs) (Iijima et al., 2004).
In MDMs, NF-kB is persistently activated and predominantly com-
posed of the RelB/p52 heterodimer (Asin et al., 2001; Nabel and
Baltimore, 1987; Neumann et al., 2000). It is conceivable that Vpr
may promote HIV-1 replication in MDMs by activating the non-
canonical NF-kB pathway.
Phosphorylation of IKKa and IKKb is regulated by multiple
mechanisms. First, IKKa and IKKb can be directly phosphorylated
by different kinases, such as NIK for IKKa, MEKK3 and TAK1
for IKKb. Second, IKK multimerization can lead to auto-phosphor-
ylation, which is mediated through interaction with other cellular
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R. Liu et al. / Virology 439 (2013) 47–5652factors including Hsp90 (Chen et al., 2002) and ELKS (Ducut Sigala
et al., 2004). It is possible that Vpr may recruit various cellular
proteins to modulate the kinase activity of IKKa/b. The different
Vpr mutants may have distinct defects in associating with these
proteins and thus exert various effects on phosphorylation of
IKKa and IKKb. Further studies are needed to explore whether Vprserves as an adaptor to recruit cellular proteins to accomplish its
multiple functions.
Abnormal production of pro-inﬂammatory cytokines and che-
mokines during HIV-1 infection is considered as a major cause of
immune dysregulation and neuron dysfunction in AIDS patients
(Douek et al., 2009). Although the effect on NF-kB activation
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Vpr-mediated NF-kB activation sufﬁce to up-regulate the expres-
sion of several cytokines, such as IL-6 and IL-8. This may assist the
virus to establish a productive infection from the very early stage
(Duverger et al., 2009). In addition, these Vpr-induced cytokines
may underlie others functions of Vpr such as induction of cell
cycle arrest and apoptosis.
In summary, results of this study demonstrate that Vpr, in the
absence of other stimuli, activates both canonical and noncano-
nical NF-kB pathway by modulating the activity of IKKa/b.
Furthermore, the endogenous IKKa/b is indispensable for Vpr-
mediated NF-kB and HIV-1 LTR activation. In addition, both
canonical and noncanonical NF-kB pathway contribute to Vpr-
mediated HIV-1 LTR activation. Our data suggest that Vpr may
assist HIV-1 to establish productive infection by elevating early
viral gene expression through activating the NF-kB pathway.Materials and methods
Plasmids
The DNA constructs 3NF-kB-Luc, pIkBa, pIkBa (AA), HA-
p65, pIKKb (AA), HA-IKKa, HA-IKKb, Flag-p100, Myc-p100 were
described previously (Diao et al., 2005; Wang et al., 2010a,
2010b). IFNb-Luc and HA-VISA were gifts from Hongbing Shu
(College of Life Sciences, Wuhan University, China). Flag-IkBa was
generated by PCR using pIkBa as a template, and cloned into the
pCMV-Tag 2B expression vector (Stratagene). The coding
sequence of human IKKg was ampliﬁed from HEK293T cDNA,then cloned into the pcDNA4 vector (Invitrogen) to generate
Myc-His-IKKg. Myc-His-NIK was ampliﬁed from HA-NIK and
cloned into pcDNA4 vector. The Flag-Vpr construct was kindly
provided by Dr. Kuan-Teh Jeang (Molecular Virology Section,
Laboratory of Molecular Microbiology, National Institutes of
Allergy and Infectious Diseases, USA) (Yedavalli et al., 2005).
pQC-Flag-Vpr was generated by PCR using Flag-Vpr as a template,
and cloned into the pQC-XIP expression vector (Clontech). HA-
IKKa (AA), Flag-p100 2SA (S866A/S870A), Flag-p100 3SA (S866A/
S870A/S872A), Flag-Vpr A30L, Flag-Vpr R77Q and Flag-Vpr S79A
were generated using site-directed PCR mutagenesis and veriﬁed
by DNA sequencing. NLENY1-DVpr was derived from NLENY1-ES-
IRES (Levy et al., 2004) by mutating the start codon AUG of vpr
gene with the following primers: sense (50-GTTAGGAAACTGACA-
GAGGACAGGTGGAACAAGCCCCAGAAGACCAAG-30); anti-sense (50-
CTTGGTCTTCTGGGGCTTGTTCCACCTGTCCTCTGTCAGTTTCCTAAC-30).
All cDNA constructs used in this study were veriﬁed by sequencing.Cell culture and transfection
HeLa and HEK293T cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium (high glucose) supplemented with 10%
fetal bovine serum (Gibco), 100 U/ml penicillin/streptomycin.
Jurkat cells were maintained in RPMI 1640 supplemented with
10% fetal bovine serum, 100 U/ml penicillin/streptomycin,
2.4 mM L-glutamine. Cells were maintained in a humidiﬁed
atmosphere containing 5% CO2 at 37 1C. HeLa and HEK293T
were transfected by PEI (Polysciences) or Lipofectamine 2000
(Invitrogen) in accordance with the manufacturer’s instructions.
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Anti-phospho-p65 (S536) (93H1), anti-phospho-IKKa/b
(Ser176/180) (16A6), anti-IKKa, anti-IKKb (2C8), anti-phospho-
IkBa (Ser32/36), anti-IkBa (L35A5), anti-phospho-NF-kB2 p100
(Ser866/870), anti-p100, anti-RelB and anti-Flag (rabbit) antibo-
dies were purchased from Cell Signaling Technology (Beverly,
MA), anti-Myc, anti-HA, anti-p65 (mouse) and horseradish
peroxidase-conjugated secondary antibodies from Santa Cruz
Biotechnology (Santa Cruz, CA), the anti-FLAG antibody (M2)
and anti-a-tubulin antibodies from Sigma. Rabbit anti-Vpr anti-
body was provided by National Institutes of Health (NIH) AIDS
Research and Reference Reagent Program. Anti-p24 antibody was
generated by immunizing mice with full length HIV-1 CA that
were puriﬁed form Escherichia coli BL21 (DE3). 40,6-diamidino-2-
phenylindole (DAPI) was purchased from Sigma. Fluor-conjugated
anti-mouse and anti-rabbit secondary antibodies were purchased
from Jackson ImmunoResearch Laboratories. Human TNF-a was
purchased from Millipore. Calyculin A was from Cell Signaling
Technology.
RNA interference
ShRNA oligos targeting IKKa or IKKb were designed by shRNA
Sequence Designer (Clontech). Double-stranded oligonucleotides
corresponding to the target sequences were cloned into the
pSIREN-RetroQ vector (Clontech). The target sequences were as
follows: NC (negative control, without speciﬁc target in cells)
(GACAGAACCAGAGGATAGA), IKKa (GAGTTAGAGGCTGTGATAG),
IKKb (GAGTGAGGTGGACATTGTT), p65 (AGCACAGATACCAC-
CAAGA), RelB (CCAGGAGCACAGATGAATT).
HEK293T cells were transfected with 1 mg pMLV-Gag-Pol,
0.5 mg pVSV-G and 1 mg pSIREN-RetroQ DNA constructs. At 48 h
post-transfection, viral supernatants were harvested to infect the
HeLa cells in the presence of polybrene (5 mg/ml) by spinoculation
at 450 g for 30 min at room temperature. After 48 h, cells were
subcultured in selection medium containing 2 mg/ml puromycin
(Sigma). Knockdown efﬁciency was assessed by Western blotting
using speciﬁc antibodies.
Viruses
VSV-G pseudotyped HIV-1 (NLENY1-ES-IRES and NLENY1-
DVpr) were produced by transfecting HEK293T cells with indi-
cated proviral DNA constructs and VSV-G plasmid. Flag-Vpr VLPs
were produced by transfecting HEK293T cells with pQC-Flag-Vpr,
MLV-Gag-Pol and VSV-G plasmids. At 48 h post-transfection, the
viral supernatants were collected, centrifuged at 200 g for
15 min to remove residual cells and debris. For VSV-G pseudo-
typed HIV-1, virus titer was determined by ELISA (Biomerieux) to
quantify viral p24 amounts. For the detection of HIV-1-elicited
phosphorylation of IkBa and p100, target cells were infected with
NLENY1-ES-IRES or NLENY1-DVpr (equivalent to 200 ng p24) in
2 ml medium for 2–3 h. For the detection of phosphorylation of
endogenous IKKa/b, p65 and p100, Jurkat cells were transduced
by spinoculation with VLP containing Flag-Vpr for 48 h.
Protein phosphorylation assay
Cells were lysed in a buffer containing 20 mM Tris (pH 7.4),
150 mM NaCl, 2 mM EDTA, 1% Triton-X-100, 1 mM sodium
orthovanadate, 50 mM sodium ﬂuoride, phosphatase inhibitor
mixture tablet (Roche), protease inhibitor cocktail tablets (com-
plete, EDTA-free) (Roche). The lysates were incubated on ice for
30 min, and then centrifuged at 13,000 g for 10 min at 4 1C.The supernatants were separated by SDS-PAGE and subjected to
Western blotting.
Immunoprecipitation and western blotting
HEK293T cells were washed twice with ice-cold 1phosphate-
buffered saline, then lysed in the buffer with 50 mM Tris (pH 7.4),
150 mM NaCl, 2 mM EDTA, 3% Glycerol, 1% NP-40, protease
inhibitor cocktail tablets (complete, EDTA-free) (Roche). The
lysates were sonicated and centrifuged at 13,000 g for 10 min
at 4 1C. Supernatants were incubated with indicated antibodies for
3 h at 4 1C, followed by further incubation with Protein A-agarose
(Millipore) for 3 h or overnight (for endogenous protein immuno-
precipitation) at 4 1C. After six times washes with high-salt lysis
buffer (250 mM NaCl), the immunocomplexes were boiled in 40 ml
2 SDS loading buffer, resolved by SDS-PAGE and transferred onto
the PVDF membrane (GE Healthcare). The membranes were
blocked in 5% non-fat milk (in 1phosphate-buffered saline) for
45 min at room temperature, and probed with the indicated
primary antibodies for 90 min at room temperature or overnight
at 4 1C. After incubation with either goat anti-rabbit or goat anti-
mouse secondary antibody, the membranes were treated with the
enhanced chemiluminescence reagents (Millipore), the protein
signals were detected by exposure to X-ray ﬁlms.
Immunoﬂuorescence microscopy assay (IFA)
As previously described (Tan et al., 2008; Wang et al., 2010a),
HeLa cells, growing on glass coverslips in 12-well plate, were
ﬁxed with 4% paraformaldehyde in 1phosphate-buffered saline
for 10 min at room temperature followed by permeabilization
with 0.1% Triton X-100 in 1phosphate-buffered saline for
10 min at room temperature. Cells were blocked with 1 ml of
3% bovine serum albumin (BSA) in 1phosphate-buffered saline
at 37 1C for 30 min. The coverslips were incubated with anti-Flag
(1:100), anti-p65 (1:100) or anti-Myc (1:200) antibodies at 37 1C
for 1 h. After washing with 1phosphate-buffered saline, cells
were further incubated with TRITC-conjugated goat anti-rabbit
and FITC-conjugated goat anti-mouse secondary antibodies
(1:200) at 37 1C for 30 min. Nuclei were stained with DAPI.
Images were recorded with Leica TCS SP5 laser scanning confocal
microscope.
Luciferase assay
HEK293T cells were seeded at a concentration of
0.2106 cells/well. The next day, cells were transfected with
the 3NF-kB-Luc or HIV-1 LTR and Flag-Vpr plasmid DNA along
with the Renilla luciferase plasmid. At 48 h after transfection,
cells were harvested in lysis buffer, and luciferase assays were
performed using the Dual-Luciferase reporter assay system (Pro-
mega). The relative luciferase activity was calculated by dividing the
ﬁreﬂy luciferase activity by the Renilla luciferase activity. Three
independent transfection experiments were performed.Acknowledgments
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